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Peter R. Kowey, MD, d Paul Chang, MD, e Daniel E. Singer, MD, MA, f Jack Ansell, MD, g Rosalia G. Blanco, BA, b
Bernard Gersh, MB, ChB, DPhil, h Kenneth W. Mahaffey, MD, i Elaine M. Hylek, MD, MPH, j Alan S. Go, MD, k
Jonathan P. Piccini, MD, MHS, a,b and Eric D. Peterson, MD, MPH a,b , for the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators Durham, NC; Los Angeles, Oakland, CA;
Wynnewood, PA; Raritan, NJ; Boston, MA; New York, NY; and Rochester, MNBackground Time in therapeutic range (TTR) of international normalized ratio (INR) of 2.0 to 3.0 is important for the
safety and effectiveness of warfarin anticoagulation. There are few data on TTR among patients with atrial fibrillation (AF) in
community-based clinical practice.
Methods Using the US Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), we examined
TTR (using a modified Rosendaal method) among 5,210 patients with AF on warfarin and treated at 155 sites. Patients were
grouped into quartiles based on TTR data. Multivariable logistic regression modeling with generalized estimating equations
was used to determine patient and provider factors associated with the lowest (worst) TTR.
Results Overall, 59%of the measured INR values were between 2.0 and 3.0, with an overall mean andmedian TTR of 65% ±
20%and 68% (interquartile range [IQR] 53%-79%). Themedian times below and above the therapeutic rangewere 17% (IQR 8%-
29%) and 10% (IQR 3%-19%), respectively. Patients with renal dysfunction, advanced heart failure, frailty, prior valve surgery, and
higher risk for bleeding (ATRIA score) or stroke (CHA2DS2-VASc score) had significantly lower TTR (P b .0001 for all). Patients
treated at anticoagulation clinics had only slightly higher median TTR (69%) than those not (66%) (P b .0001).
Conclusions Among patients with AF in US clinical practices, TTR on warfarin is suboptimal, and those at highest
predicted risks for stroke and bleeding were least likely to be in therapeutic range. (Am Heart J 2015;170:141-148.e1.)Atrial fibrillation (AF) is the most common arrhythmia in
clinical practice, and hospitalizations because of AF are
increasing.1 Patients with AF have a 5- to 7-fold greater risk
of stroke than the general population.2-4 Oral anticoagulants
can effectively decrease the stroke rate by more than two
thirds; however, this therapy also puts patients at increased
risk for bleeding and intracranial hemorrhage.5-7ical Research Institute,
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hThe clinical benefit and risks of warfarin are associated
with the proportion of time that international normalized
ratio (INR) values are between 2 and 3,meaning the time in
therapeutic range (TTR).8 To date, only a few multicenter
studies have examined patients’ TTR in clinical practice in
the United States. These studies, however, had limited
sample size,9 failed to explore patient-level clinical data,10
or were not generalizable to the overall population.11
Theobjectiveof this analysis is to describepatient-level TTR
within the nation’s largest community-based AF clinical
registry. The detailed clinical data on the patients in this study
provide insight into characteristics of patients associatedwith
low TTR, who may be predicted to be candidates for
alternatives to non–vitamin K oral anticoagulants (NOAC).Methods
Study population
The Outcomes Registry for Better Informed Treatment
of Atrial Fibrillation (ORBIT-AF) is a US national prospec-
tive registry of AF.12 Enrolling providers include primary
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July 2015care physicians’, cardiologists’, and electrophysiologists’
clinics. Eligible patients are at least 18 years of age with
nonreversible AF that has been documented on an
electrocardiogram. Patients were excluded if they had a
life expectancy of b6 months or were not capable of at
least 2 years of follow-up.
Sites entered data from the medical record into a web-
based case report form at baseline and every 6 months
over longitudinal follow-up. Patient demographics, med-
ical history, AF history, AF symptoms, AF treatment
strategy, vital signs, laboratory data, imaging data,
incident procedures, and adverse events were collected.
The Duke Clinical Research Institute was responsible for
study design and data management.
There were 10,132 consecutive patients from 176
clinic sites enrolled in ORBIT-AF from June 2010 through
August 2011. Patients were excluded from this analysis if
they were not on warfarin at baseline (n = 2,918) or did
not have documented INR data at follow-up (n = 1,201).
This analysis is intended to evaluate patients on long-term
warfarin therapy, so patients with b5 INR values were
excluded (n = 803). The final study population included
5,210 patients, who were enrolled at 155 sites.
Time in therapeutic range calculation
A modified Rosendaal method of linear interpolation
was used between each pair of measured INR values.13
Daily INR values were imputed between each measured
INR. No extrapolation was performed before the baseline
visit at the time of registry enrollment or after the end of
follow-up. For patients with time between any 2
measurements of ≥60 days (4.8% of the intervals
between 2 INR measurements), this time span was
excluded from the TTR calculation. A sensitivity analysis
calculated the overall TTR without excluding any time
spans. The TTR was calculated as the proportion of days
with INR values between 2 and 3. An INR value of b2.0
was defined as subtherapeutic, and an INR value N3.0 was
defined as supratherapeutic.
Statistical methods
Patients were stratified into quartiles based on TTR.
Baseline characteristics were determined for the overall
population and by quartile. Categorical variables were
defined as frequencies and percentages, and differences
between the groups were assessed by the χ2 test.
Continuous variables were characterized by median
(interquartile range [IQR]), and differences between the
groups were determined by the Kruskal-Wallis test.
Patients in the lowest TTR quartile were considered
to be poor responders to warfarin. A multivariable
logistic regression model with generalized estimating
equations was constructed for the outcome of poor
responders (quartile 1) versus non–poor responders
(quartiles 2-4), using clinical and demographic charac-
teristics (online Appendix).All continuous variables were evaluated for nonlinearity
with the outcome, and variables that did notmeet the linear
relationship criteria (P b .05) were accounted for using
linear splines. Missing data were 4% for level of education,
6% for chronic kidney disease (CKD), 9% for hemoglobin
level, and b1% for all remaining covariates. Missing data on
the covariates were imputed using multiple imputation.
Backward selection with an inclusion criterion of 0.05 was
performed on the first imputed data set to obtain a set of
factors that were independently associated with poor
responders. For each imputed data set, a model with the
significant covariates was fit using a logistic generalized
estimating equations method with exchangeable working
correlation matrix to account for intrasite clustering.
Patients at the same site are more likely to have similar
responses relative to patients at other sites (ie, within-center
correlation for responses).14 The results from each model
were then combined. All analyses were performed using
SAS software (version 9.3, SAS Institute, Cary, NC). The
ORBIT-AF registry is sponsored by Janssen Scientific Affairs,
LLC, Raritan, NJ. The authors are solely responsible for the
design and conduct of this study, all study analyses, the
drafting and editing of themanuscript, and its final contents.Results
Baseline characteristics
Among the 5,210patientswithAF included in this analysis,
there were 119,842 INR measurements over a median of
18 months (IQR 12-23 months) of follow-up. The median
number of INR draws per patient was 20 (IQR 12-30).
Among all measured INR values, the median INR value was
2.3 (IQR2.0-2.8), and 59%of allmeasured INR valueswere in
the therapeutic range, whereas 25% of all INR values were
b2.0, and17%wereN3.0. Themean andmedianpatient-level
TTRs were 65% ± 20% and 68% (IQR 53%-79%), respectively
(Figure 1). The median times that individual patients spent
below and above the therapeutic range were 17% (IQR 8%-
29%) and 10% (IQR 3%-19%), respectively.
The frequency of INR checks was associated with INR
results. Specifically, the mean number of days between
INR measurements was 21 to 24 days for patients with
INR values within the therapeutic range (ie, 2.0-3.0),
whereas patients with subtherapeutic or supratherapeu-
tic values had their INR tested more frequently (Figure 2).
The median number of INR draws per month was also
higher among the quartile of patients with the highest
TTR: 0.86 INR draws per month (IQR 0.72-1.08) for
quartile 4, 0.78 (IQR 0.64-0.99) for quartile 3, 0.75 (IQR
0.56-0.98) for quartile 2, and 0.72 (IQR 0.51-1.00) for
quartile 1 (P b .0001).
The patients within the lowest quartile TTR (ie, TTR
≤53) were more often female, nonwhite, and had less
college education than those with higher TTRs. Patients
with comorbidities, including diabetes, CKD, and heart
failure, were also less likely to have high TTR (Table).
Figure 1
Distribution of INR measurements with median TTR and median time
above/below therapeutic range displayed.
Figure 2
ean number of days until subsequent INR check based on INR values.
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A multivariable model was designed to identify factors
associated with individual patients being in the lowest
quartile of TTR (Figure 3). Advanced heart failure, frailty,
and prior valve surgery were some of the factors with the
highest odds ratios for association with low TTR.
Warfarin management by an anticoagulation clinic and
diagnosis of AF b1 year from ORBIT-AF enrollment were
both associated with lower odds of having low TTR.
Patient-level TTR also varied as a function of CHA2DS2-
VASc scores (Figure 4, A). There were 268 patients with
CHA2DS2-VASc scores of 0 or 1, who were on long-term
warfarin, and these patients had a TTR of 70% (IQR 58%-
82%). Most patients in the analysis (n = 2,860) had a
CHA2DS2-VASc score of 2 to 4, and these patients had a
median TTR of 69% (IQR 55%-80%). Patients with a high
CHA2DS2-VASc score of ≥5 had a statistically significant
lower median TTR of 65% (IQR 51%-77%), relative to
patients with a CHA2DS2-VASc score of 0 or 1 (P b .001).
Variations by ATRIA score yielded similar findings
(Figure 4, B). Patients with a high ATRIA score of≥5 (n =
893) had a statistically significant lower median TTR of
65% (IQR 50%-77%), compared with patients with an
ATRIA score of 0 to 3 (median TTR 68% [IQR 54%-80%],
P b .001).
The multivariable model demonstrated that decreasing
creatinine clearance b60 mg/dL was associated with a
patient having a TTR in the lowest quartile (odds ratio
1.08 per 5 mg/dL decrease [95% CI 1.05-1.11, P b .001]).
Patients with stage 3, 4, and 5 chronic kidney disease
(CKD) had significantly lower TTR relative to patients
with stage 1 or 2 CKD (Figure 4, C). Patients with stage 4
CKD had statistically lower TTR than patients with
stage 3 CKD (63% vs 66%, P = .011), and the same
relationship was true for stage 5 versus stage 3 CKD (47%
vs 66%, P b .001).MSite level variation
There was significant variation in median TTR by site
(online Appendix) with an overall median site TTR of
67% (IQR 61%-71%). There were nearly 3% of sites with a
median TTR of 50% to 55%, compared with 2% of sites
with median TTR ≥80%. Warfarin patients followed at
anticoagulation clinics had higher median TTR (69%,
IQR 55%-80%) than those patients not followed at
anticoagulation clinics (66%, IQR 51%-78%) (P b .0001).
There was minimal geographic variation of TTR with
median TTR values of 68% (IQR 55%-79%) for the
Midwest, 68% (IQR 53%-80%) for the Northeast, 67%
(IQR 52%-78%) for the South, and 67% (IQR 53%-79%) for
the West (P = .12).
Sensitivity analysis of TTR
A sensitivity analysis was performed for the exclusion
of interpolated INR values between 2 measured INRs that
were at least 60 days apart, which represented 4.8% of
the intervals between 2 INR measurements. This was
done by including all interpolated INR values between
the first and last measured INR for all patients with at least
5 measured INR values. This methodology yielded an
identical median TTR of 68%. The IQR of 52% to 80% was
nearly the same as the IQR from the main analysis (53%-
79%).Discussion
Overall, we found that only 59% of all INR values drawn
on patients with AF on warfarin were in a therapeutic
range (INR 2-3), resulting in a median patient-level TTR of
68%. Time in therapeutic range varied across the patient
population, and of concern, we found that patients with
the highest risk of bleeding and stroke had paradoxically
Table. Patient characteristics
Variable
Overall,
N = 5,210
Quartile 1 (TTR 0%-
53%), N = 1,131
Quartile 2 (TTR 54%-
67%), N = 1,267
Quartile 3 (TTR 68%-
79%), N = 1,353
Quartile 4 (TTR 80%-
100%), N = 1,259 P
Demographics
Age, mean (SD) 75 (10) 74 (11) 75 (10) 75 (9) 75 (9) .51
Female sex 2,218 (43%) 595 (45%) 579 (46%) 570 (42%) 474 (38%) b.001
White race 4,714 (90%) 1,166 (88%) 1,146 (90%) 1,234 (91%) 1,168 (93%) .003
College education 1,552 (30%) 336 (25%) 376 (30%) 423 (31%) 417 (33%) b.001
Insurance status b.001
Medicare 3,666 (70%) 902 (68%) 904 (71%) 975 (72%) 885 (70%)
Medicaid 216 (4%) 87 (7%) 57 (5%) 40 (3%) 32 (3%)
Private 1,096 (21%) 289 (22%) 248 (20%) 278 (21%) 281 (22%)
Past medical history
Anemia 975 (19%) 296 (22%) 255 (20%) 217 (16%) 207 (16%) b.001
Frailty 276 (5%) 99 (7%) 82 (6%) 55 (4%) 40 (3%) b.001
Chronic obstructive
pulmonary disease
868 (17%) 279 (21%) 234 (18%) 198 (15%) 157 (12%) b.001
Hypertension 4,475 (86%) 1,162 (87%) 1,084 (86%) 1,162 (86%) 1,067 (85%) .30
Diabetes 1,587 (30%) 486 (37%) 409 (32%) 355 (26%) 337 (27%) b.001
Chronic kidney disease 1,898 (36%) 548 (41%) 469 (37%) 488 (36%) 393 (31%) b.001
Prior gastrointestinal bleed 424 (8%) 133 (10%) 97 (8%) 106 (8%) 88 (7%) .031
Obstructive sleep apnea 980 (19%) 274 (21%) 260 (21%) 248 (18%) 198 (16%) .004
Peripheral vascular disease 737 (14%) 219 (16%) 189 (15%) 190 (14%) 139 (11%) b.001
Prior cerebrovascular event 915 (18%) 251 (19%) 232 (18%) 229 (17%) 203 (16%) .24
Heart failure 1,866 (36%) 582 (44%) 466 (37%) 462 (34%) 356 (28%) b.001
Risk stratification
CHADS2 score, mean (SD) 2.4 (1.2) 2.6 (1.3) 2.5 (1.3) 2.4 (1.2) 2.3 (1.2) b.001
CHA2DS2-VASc score, mean (SD) 4.1 (1.6) 4.3 (1.7) 4.2 (1.7) 4.1 (1.6) 3.9 (1.6) b.001
ATRIA bleeding score, mean (SD) 2.8 (1.9) 3.0 (2.0) 2.9 (1.9) 2.8 (1.9) 2.7 (1.8) b.001
Site characteristics
Anticoagulation clinic 2,545 (49%) 577 (43%) 624 (49%) 685 (51%) 659 (52%) b.001
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management through anticoagulation clinics had only
slightly higher TTR than those managed in regular clinics.
The TTR value has been shown to be associated with
clinical outcomes. This was first demonstrated in
observational data from the Stroke Prevention Using an
Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF)
III and V trials, in which patients were divided into TTR
tertiles of b60%, 60%-75%, and N75%, and the analysis
found that patients in the lowest tertile had higher rates
of mortality, major bleeding, and stroke relative to the
highest tertile.15 The Atrial fibrillation Clopidogrel Trial
with Irbesartan for prevention of Vascular Events
(ACTIVE W) trial evaluated the association of center
TTR and outcomes.8 The median center TTR in ACTIVE
Wwas 65%, and warfarin administration reduced vascular
events compared with the combination of aspirin and
clopidogrel when center TTR was N65%. Population
modeling based on the data from ACTIVE W determined
that a TTR b58% would not generate a net clinical benefit.
These findings are consistent with a secondary analysis
from the Randomized Evaluation of Long-Term Antic-
oagulation Therapy (RE-LY trial) that showed that
dabigatran had the greatest advantage over warfarin in
prevention of stroke and systemic embolism among
patients at centers with the lowest TTR.16 However, theeffects of rivaroxaban and apixaban were similar across a
range of center TTRs.17,18
Historical US data identified lower therapeutic rates of
warfarin in clinical practice than in clinical trials with
only 50% of INR values being therapeutic in clinical
practice in the early 1990s.19 A more contemporary study
of 392 patients with AF in the United States identified a
mean TTR of 57% with warfarin management by a mix of
primary care and specialists.9 This finding was consistent
with a mean TTR of 58% among 100 Veterans Affairs
clinics11 as well as a large, recently published analysis of
data from Quest Diagnostics that identified a mean
TTR of 54% among nearly 140,000 patients in the
United States.10 The median TTR value in our study was
the same as was seen in the clinical trial that compared
edoxaban with warfarin in AF patients (median TTR
68%), and the edoxaban trial had the highest TTR of the
NOAC trials.20 The higher TTR in our analysis relative to
what was reported by Dlott et al10 could be caused by
several factors. The INR target for patients is not known
in our analysis or the Quest study, and lower INR targets
in the Quest analysis could have resulted in subtherapeu-
tic values 31% of the time versus 17% in our analysis. Our
registry patients may have been more ambulatory, less
sick, more adherent to medications, and better able to
follow-up with frequent INR monitoring, which could
Figure 3
eGFR = estimated glomerular filtration rate by MDRD. COPD = chronic obstructive pulmonary
disease
Factors associated with TTR in the lowest quartile (≤53%).
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Volume 170, Number 1explain the higher TTR in the ORBIT-AF population. In
addition, Dlott et al noted that most providers in their
data were low-volume providers, and higher volume
providers, which may represent anticoagulation clinics,
had higher mean TTR values. One key difference
between our data and the Quest data is that the types
of clinics are more clearly defined in ORBIT-AF, and
nearly half of the patients in ORBIT-AF were followed by
anticoagulation clinics, which could also explain the
difference in TTR values between the 2 studies.
Patients with lower TTR derive less benefit from
warfarin, so it would be valuable to be able to identify
patients at risk for low TTR at the time of OAC initiation.
Unlike ORBIT-AF, the study by Dlott et al did not have
access to detailed clinical data but did find that younger
age, female sex, and lower income were independently
associated with low TTR.10 Similarly, we identified
younger age as a risk factor for low TTR. Our findings
also identified multiple comorbidities such as frailty,
heart failure, CKD or lower estimated glomerular
filtration rate, chronic obstructive pulmonary disease,
and diabetes as risk factors for low TTR. Diabetes and
heart failure have previously been shown to be associated
with subtherapeutic INR values in the Anticoagulation
Consortium to Improve Outcomes Nationally (ACTION)
study.21 The SAME-TT2R2 score has been developed and
validated as a tool to predict TTR.22,23 A higher score isassociated with a lower TTR. Female sex, race, and
smoking status are components of the SAME-TT2R2 score ,
and these factors were not associated with being in the
lowest quartile of TTR in our model. Both the SAME-
TT2R2 score and our model identified multiple comor-
bidities as being associated with lower TTR, and both
stroke risk by CHA2DS2-VASc and bleeding risk by ATRIA
are driven by comorbid conditions. It may be the
comorbid disease states themselves that result in the
finding seen in this manuscript that patients at higher risk
for stroke or bleeding have lower TTR. This observation
was not described in previous TTR analyses, and it
emphasizes the importance of close follow-up for
warfarin patients at increased risk for stroke or bleeding.
Decision support tools for warfarin dosing may represent
a future opportunity to further increase TTR,24 whereas a
pharmacogenetic warfarin algorithm has been studied in
a US randomized trial with no short-term improvement in
TTR over a clinical algorithm.25
Our analysis did show that INR management by an
anticoagulation clinic was protective against low TTR
with an odds ratio of 0.71 (95% CI 0.63-0.81), whereas
TTR in anticoagulation clinics was slightly higher than
that of non-anticoagulation clinics (69% vs 66%). Antic-
oagulation clinics may be serving a self-selected group of
patients. The increased use and homogeneity of antic-
oagulation clinics in Europe26 may, at least in part,
Figure 4
A, TTR by CHA2DS2-VASc score. B, TTR by ATRIA score. C, TTR by
stage of chronic kidney disease.
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July 2015explain the higher TTR values of 68% in Germany,27 76%
in Sweden,28 and 83% in Denmark.24 Patients with
multiple factors associated with low TTRmay not be ideal
candidates for warfarin therapy, and these patients
should be considered for a NOAC.
Limitations
This analysis has several important limitations. There
were 1,201 patients excluded because INR data werenot available, and it is possible that this group of
patients would have affected the results had their data
been available. The target INR range for patients was
not known. Although the standard goal is 2.0 to 3.0, it is
possible that some physicians may have set a lower goal
of 1.5 to 2.5 in patients with higher risk of bleeding. The
study describes variations in INR and TTR, but there are
no associated outcomes that may allow for determina-
tions of the clinical impact of TTR variation. Periods of
N60 days between 2 INR measurements were excluded
from the TTR calculation, but the reasons for gaps
between INR measurements are not known. Despite
this, a sensitivity analysis demonstrated that the
inclusion of these gaps in the TTR calculation did not
meaningfully change the results. Residual measured
and unmeasured confounding may have influenced
these findings. We were unable to account for
medication nonadherence as a risk factor for low
TTR. If patients have a low TTR because of nonadher-
ence with warfarin, they may be at greater risk of
adverse events with shorter-acting NOACs. Finally,
ORBIT-AF investigators may not be representative of
all US providers, which may limit the generalizability of
these findings.
In US clinical practices, warfarin patients are in the
therapeutic range about two thirds of the time. Patients at
highest risk for stroke and bleeding were least likely to be
in the therapeutic range. Finally, there was variation in
TTR between sites, with anticoagulation clinics having
the highest overall TTR.Acknowledgements
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